文献速递胸部肿瘤

临床消退的浸润前鳞状肺癌中的免疫监视

Immune Surveillance in Clinical Regression of Preinvasive Squamous Cell Lung Cancer.
PubMed 文献 · Cancer Discov · 2020-07-20

本研究利用支气管镜活检的人体样本,发现消退的原位癌病变比进展为癌的病变更富含浸润免疫细胞。进展为癌的病变存在抗原提呈受损、CCL27-CCR10信号上调及TNFSF9下调等免疫逃逸机制,且这些改变为原位癌病变内在性,因进展与消退病变的邻近间质转录组相似。

要点

  • 消退的原位癌病变免疫细胞浸润多于进展为癌的病变。
  • 进展病变存在抗原提呈受损、CCL27-CCR10上调及TNFSF9下调。
  • 免疫逃逸改变为原位癌病变内在性,间质转录组相似。

核心结论

  • 宿主免疫监视与浸润前鳞状肺癌的临床消退密切相关。

研究设计与样本

  • 基于人体受试者支气管镜活检样本的观察性研究。

主要发现

  • 消退的原位癌病变比进展为癌的病变有更多浸润免疫细胞。
  • 进展为癌的病变显示抗原提呈因基因组和表观遗传改变而受损。
  • 进展为癌的病变中CCL27-CCR10信号上调且免疫调节因子TNFSF9下调。
  • 进展与消退病变的邻近间质转录组相似,提示改变为原位癌内在性。

临床怎么用

  • 为治疗或预防早期肺癌的新策略提供了基础。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Before squamous cell lung cancer develops, precancerous lesions can be found in the airways. From longitudinal monitoring, we know that only half of such lesions become cancer, whereas a third spontaneously regress. Although recent studies have described the presence of an active immune response in high-grade lesions, the mechanisms underpinning clinical regression of precancerous lesions remain unknown. Here, we show that host immune surveillance is strongly implicated in lesion regression. Using bronchoscopic biopsies from human subjects, we find that regressive carcinoma in situ lesions harbor more infiltrating immune cells than those that progress to cancer. Moreover, molecular profiling of these lesions identifies potential immune escape mechanisms specifically in those that progress to cancer: antigen presentation is impaired by genomic and epigenetic changes, CCL27-CCR10 signaling is upregulated, and the immunomodulator TNFSF9 is downregulated. Changes appear intrinsic to the carcinoma in situ lesions, as the adjacent stroma of progressive and regressive lesions are transcriptomically similar. SIGNIFICANCE: Immune evasion is a hallmark of cancer. For the first time, this study identifies mechanisms by which precancerous lesions evade immune detection during the earliest stages of carcinogenesis and forms a basis for new therapeutic strategies that treat or prevent early-stage lung cancer.See related commentary by Krysan et al., p. 1442.This article is highlighted in the In This Issue feature, p. 1426.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Pennycuick A, Teixeira VH, AbdulJabbar K, et al. Immune Surveillance in Clinical Regression of Preinvasive Squamous Cell Lung Cancer. Cancer Discov. 2020. PMID: 32690541. doi:10.1158/2159-8290.CD-19-1366

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。